Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota.
Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Clin Gastroenterol Hepatol. 2022 Feb;20(2):458-460.e4. doi: 10.1016/j.cgh.2021.03.031. Epub 2021 Mar 26.
Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events. Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma. Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.
非酒精性脂肪性肝病（NAFLD）患者患心血管疾病的风险增加。羟甲基戊二酰辅酶 A 还原酶抑制剂，即他汀类药物，可降低心血管事件的风险。研究表明，他汀类药物在肝病患者中是安全的，包括代偿性肝硬化患者，其使用与死亡率降低、肝功能失代偿和可能的肝细胞癌有关。尽管有这些数据，但由于担心肝毒性，他汀类药物在肝病患者中的使用仍不足。本研究旨在评估在真实世界队列中，NAFLD 患者中与他汀类药物适应证使用相关的患病率和患者因素。
